Gilead Sciences (GILD) Accumulated Expenses (2009 - 2022)

Gilead Sciences (GILD) has reported Accumulated Expenses for 14 consecutive years, with $3.7 billion the latest figure, recorded in Q3 2022.

• Accumulated Expenses for Q3 2022 came in at $3.7 billion, down 2.83% year-over-year; the trailing twelve-month figure through Sep 2022 was $3.7 billion (down 2.83% YoY), and the FY2021 annual result was $3.2 billion, down 25.18% from the prior year.
• Accumulated Expenses was $3.7 billion for Q3 2022 at Gilead Sciences, down from $4.1 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $5.0 billion in Q1 2018 and troughed at $2.3 billion in Q1 2019.
• Average Accumulated Expenses over 5 years is $3.7 billion, with a median of $3.7 billion recorded in 2019.
• Year-over-year, Accumulated Expenses tumbled 53.49% in 2019 and surged 47.23% in 2020.
• Over 5 years, Accumulated Expenses stood at $3.9 billion in 2018, then dropped by 11.58% to $3.5 billion in 2019, then rose by 24.85% to $4.3 billion in 2020, then declined by 25.18% to $3.2 billion in 2021, then increased by 13.26% to $3.7 billion in 2022.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $3.7 billion in Q3 2022, $4.1 billion in Q2 2022, and $3.4 billion in Q1 2022.